Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

Written by | 24 Feb 2022

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men… read more.

Lab results show promise for future pancreatic cancer treatment

Written by | 13 Feb 2022

University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that… read more.

New treatment emerges for difficult-to-treat form of ovarian cancer

Written by | 9 Feb 2022

Trametinib, a drug treatment for skin and lung cancers, appears to slow the progression of low-grade serous cancer of the ovary and to increase the number of patients… read more.

Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet – Genentech/Roche

Written by | 8 Feb 2022

Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.

Updated results from pivotal HER2CLIMB trial evaluating Tukysa in patients with HER2-positive breast cancer – Seagen Inc

Written by | 6 Feb 2022

Seagen Inc. announced the presentation of new data from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in overall survival (OS) was maintained after an additional… read more.

Researchers discover how lactic acid weakens anti-tumor defenses

Written by | 3 Feb 2022

In cancer research, it has long been known that lactic acid, or lactate, is produced in large quantities by cancer cells and that this lactic acid disrupts our… read more.

Lung cancer – urgent action required to get back on track

Written by | 3 Feb 2022

Two recent reports show how hard lung cancer outcomes have been impacted as a result of the covid-19 pandemic, according to Professor Robert Rintoul, chair of the UK… read more.

European Commission approves Lenvima + Keytruda to treat endometrial carcinoma – Eisai + Merck Inc.

Written by | 29 Jan 2022

Eisai Co., Ltd. and Merck Inc., announced that the European Commission has approved the combination of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai,… read more.

Researchers develop optical biopsy system that detects liver cancer

Written by | 20 Jan 2022

New instrument could aid diagnosis by helping surgeons pinpoint the best place for a biopsy. Researchers have developed an optical biopsy system that can distinguish between cancerous and… read more.

Glucose control lowers risk of cancer in obese diabetic patients

Written by | 18 Jan 2022

Blood glucose control is key to lowering the risk of cancer in obese persons with type 2 diabetes, researchers reported on Dec. 6, 20231 in Diabetes Care. “What… read more.

Possibility of vaccine to prevent skin cancer

Written by | 17 Jan 2022

Research by the Oregon State University College of Pharmacy suggests that a vaccine stimulating production of a protein critical to the skin’s antioxidant network could help people bolster… read more.

Sorting cancers by ‘immune archetypes’ represents potential new approach to developing precision immunotherapies

Written by | 16 Jan 2022

Common immune microenvironments across different types of cancer. Using data from over 300 patient tumors, researchers have described 12 classes of ‘immune archetypes’ to classify cancer tumors. Their… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.